TAM
ACAD icon

Tocqueville Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Tocqueville Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,150
Closed -$597K – 737
2021
Q1 		$597K Buy
+23,150
New +$1.02M 0.01% 521
2020
Q3 		– Sell
-13,625
Closed -$660K – 648
2020
Q2 		$660K Hold
13,625
– – 0.01% 445
2020
Q1 		$576K Hold
13,625
– – 0.01% 431
2019
Q4 		$583K Sell
13,625
-19,900
-59% -$866K 0.01% 528
2019
Q3 		$1.21M Sell
33,525
-35,543
-51% -$1.08M 0.02% 437
2019
Q2 		$1.85M Sell
69,068
-23,800
-26% -$608K 0.02% 399
2019
Q1 		$2.49M Buy
92,868
+41,000
+79% +$958K 0.03% 365
2018
Q4 		$839K Hold
51,868
– – 0.01% 484
2018
Q3 		$1.08M Buy
51,868
+33,168
+177% +$522K 0.01% 491
2018
Q2 		$286K Sell
18,700
-14,480
-44% -$258K ﹤0.01% 704
2018
Q1 		$746K Buy
33,180
+2,020
+6% +$55.9K 0.01% 549
2017
Q4 		$938K Sell
31,160
-14,100
-31% -$451K 0.01% 516
2017
Q3 		$1.71M Sell
45,260
-55,300
-55% -$1.8M 0.02% 469
2017
Q2 		$2.81M Buy
100,560
+610
+0.6% +$18.2K 0.03% 376
2017
Q1 		$3.44M Buy
99,950
+6,675
+7% +$236K 0.04% 350
2016
Q4 		$2.69M Sell
93,275
-31,850
-25% -$843K 0.03% 371
2016
Q3 		$3.98M Buy
125,125
+12,725
+11% +$431K 0.05% 324
2016
Q2 		$3.65M Buy
112,400
+16,750
+18% +$561K 0.04% 334
2016
Q1 		$2.67M Buy
95,650
+41,660
+77% +$908K 0.04% 361
2015
Q4 		$1.93M Buy
53,990
+1,750
+3% +$61.7K 0.03% 431
2015
Q3 		$1.73M Buy
52,240
+1,200
+2% +$49.9K 0.02% 464
2015
Q2 		$2.14M Buy
51,040
+100
+0.2% +$3.87K 0.03% 458
2015
Q1 		$1.66M Buy
50,940
+12,140
+31% +$417K 0.02% 504
2014
Q4 		$1.23M Buy
38,800
+15,000
+63% +$425K 0.01% 543
2014
Q3 		$589K Hold
23,800
– – 0.01% 582
2014
Q2 		$538K Buy
+23,800
New +$497K 0.01% 707

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Tocqueville Asset Management's ACAD Position: Q2 2021 in Review

Tocqueville Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 23,150 shares — an estimated $597K sold.

Tocqueville Asset Management first reported a position in ACAD in Q2 2014 and held it in 26 quarters. The position peaked at $3.98M in Q3 2016. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Tocqueville Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Tocqueville Asset Management sold 23,150 Acadia Pharmaceuticals shares in Q2 2021, an estimated $597K.
  • Tocqueville Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and held it in 26 quarters.
  • Tocqueville Asset Management's Acadia Pharmaceuticals position peaked at $3.98M in Q3 2016.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Tocqueville Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.